VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.

[1]  K. Stergiopoulos,et al.  Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis , 2009, Acta oncologica.

[2]  V. D’Agati,et al.  Glomerular disease related to anti-VEGF therapy. , 2008, Kidney international.

[3]  E. Small,et al.  Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Robert,et al.  Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  E. Vokes,et al.  Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Jardine,et al.  The Relationship between Proteinuria and Coronary Risk: A Systematic Review and Meta-Analysis , 2008, PLoS medicine.

[7]  Kwanghee Kim,et al.  The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A , 2008, Nature Medicine.

[8]  P. Bycott,et al.  Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study , 2008, The Lancet.

[9]  A. Chen,et al.  Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial , 2008 .

[10]  F. Goldwasser,et al.  Skin toxicity of sunitinib: Prospective analysis in patients (pts) with metastatic renal cell carcinoma (mRCC) , 2008 .

[11]  C. Alpers,et al.  VEGF inhibition and renal thrombotic microangiopathy. , 2008, The New England journal of medicine.

[12]  G. Demetri,et al.  A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. , 2008, Journal of the National Cancer Institute.

[13]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[14]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[15]  R. Motzer,et al.  Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. , 2007, The Lancet. Oncology.

[16]  S. Doucette,et al.  Renin Angiotensin System Blockade in Kidney Transplantation: A Systematic Review of the Evidence , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  Yuan Zhang,et al.  Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions , 2007, Proceedings of the National Academy of Sciences.

[18]  J. Barratt,et al.  Urine proteomics: the present and future of measuring urinary protein components in disease , 2007, Canadian Medical Association Journal.

[19]  H. Izzedine,et al.  Interstitial nephritis in a patient taking sorafenib. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  H. Izzedine,et al.  Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  R. Figlin,et al.  Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT) , 2007 .

[22]  R. Herbst,et al.  Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum- and erlotinib- resistant adenocarcinoma of the lung (NSCLA) , 2007 .

[23]  J. Villano,et al.  Examining ethnic differences for bevacizumab-induced hypertension and proteinuria , 2007 .

[24]  G. Pond,et al.  Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium , 2007 .

[25]  A. Oza,et al.  VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study , 2007 .

[26]  H. Izzedine,et al.  Thrombotic microangiopathy and anti-VEGF agents. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  B. Rovin,et al.  Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma , 2007, Nature Clinical Practice Nephrology.

[28]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Kalluri,et al.  Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  W. Dahut,et al.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  R. Toto,et al.  Nephrotic syndrome after bevacizumab: case report and literature review. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  D. Nochy,et al.  Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. , 2007, The Lancet. Oncology.

[33]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[34]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[35]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[36]  K. Altundag,et al.  Angiotensin-Converting Enzyme Inhibitors for Bevacizumab-Induced Hypertension , 2006, The Annals of pharmacotherapy.

[37]  M. Saleem,et al.  Direct effects of dexamethasone on human podocytes. , 2006, Kidney international.

[38]  J. Verweij,et al.  An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Hara,et al.  Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. , 2006, Kidney international.

[40]  Jaakko Patrakka,et al.  Hereditary proteinuria syndromes and mechanisms of proteinuria. , 2006, The New England journal of medicine.

[41]  Betty Y. Y. Tam,et al.  VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. , 2006, American journal of physiology. Heart and circulatory physiology.

[42]  D. Cunningham,et al.  Managing Patients Treated with Bevacizumab Combination Therapy , 2005, Oncology.

[43]  F. Epstein,et al.  Preeclampsia: a renal perspective. , 2005, Kidney international.

[44]  J. Berlin,et al.  Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  G. Bakris,et al.  The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. , 2005, Archives of internal medicine.

[46]  E. Lewis,et al.  Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[47]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Y. Sugisaki,et al.  Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis. , 2004, Journal of the American Society of Nephrology : JASN.

[49]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[50]  A. Flyvbjerg,et al.  The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. , 2004, Kidney international.

[51]  Zhongxin Zhang,et al.  Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.

[52]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Bruce Kupelnick,et al.  K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease , 2004 .

[54]  F. Gündüz,et al.  Effect of nitric oxide on exercise-induced proteinuria in rats. , 2003, Journal of applied physiology.

[55]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[56]  R. Kalluri,et al.  Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria* , 2003, The Journal of Biological Chemistry.

[57]  J. Haigh,et al.  Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. , 2003, The Journal of clinical investigation.

[58]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .

[59]  G. Curhan,et al.  Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. , 2002, Journal of the American Society of Nephrology : JASN.

[60]  P. Fine,et al.  Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. , 2001, Journal of the American Society of Nephrology : JASN.

[61]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[62]  S. Morcos,et al.  Effect of iodinated water soluble contrast media on urinary protein assays. , 1992, BMJ.

[63]  A. Hutchison,et al.  Albumin excretion rate, albumin concentration, and albumin/creatinine ratio compared for screening diabetics for slight albuminuria. , 1988, Clinical chemistry.

[64]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[65]  G. Bakris.  Slowing nephropathy progression: focus on proteinuria reduction. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[66]  D. López,et al.  ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis. , 2005, Kidney international. Supplement.

[67]  E. Agabiti-Rosei.  [Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy]. , 2003, Drugs.

[68]  Enrico Agabiti-Rosei.  Modifications structurelles et fonctionnelles de la microcirculation dans l’hypertension: Influence du traitement pharmacologique , 2003 .

[69]  B. Rose.  Pathophysiology of Renal Disease , 1981 .